Clotrimazole topical spray 1%
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Topical spray solution containing clotrimazole.
Fungal infection of skin
The topical spray is particularly useful for infections covering large or hairy areas.
Apply 2 - 3 times daily.
Dermatophyte infections: treat for at least 4 weeks.
Candida infections: treat for at least 2 weeks.
Pityriasis versicolor: treat for at least 2 weeks.
Precautions and Warnings
Contains propylene glycol: may cause irritation
Avoid contact with ears
Avoid contact with mucous membranes
Avoid use in or near eyes
Avoid inhalation of the product
Flammable : Advise patient not to operate spray near naked flames
Pregnancy and Lactation
Use clotrimazole with caution in pregnancy under the supervision of a physician or midwife.
Some studies on exposed pregnancies found no association with adverse effects on the health of the foetus or neonate. However, one study did find significant increase in the risk of spontaneous abortions with first trimester vaginitis treatment.
Schaefer (2015) considers clotrimazole and miconazole as the topical antimycotics of choice in pregnancy.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Use clotrimazole with caution in breastfeeding.
It is not known if clotrimazole, applied topically is distributed into breast milk. It has been used without adverse effects for some considerable time. Clotrimazole has poor oral bioavailability, it is unlikely to adversely affect the breastfed infant.
Any excess should be removed from the nipples before nursing.
Schaefer (2015) considers clotrimazole and nystatin as the local antimycotics of choice during breastfeeding.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Blisters (application site)
Irritation at application site
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: February 2018
Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.
Summary of product characteristics: Canesten Dermatological Spray 1%. Bayer Plc. Revised July 2015.
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Clotrimazole. Last revised: September 07, 2013
Last accessed: February 09, 2018
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.